Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination

Several central and peripheral nervous system complications associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection have been recently described. An effective mass vaccination program is necessary to effectively reduce infection spread and, consequently, limit long-term sequelae, including those affecting the nervous system. Nevertheless, as more patients gain access to coronavirus disease 2019 (COVID-19) vaccines, it is important to report potential adverse events. Herein, we report a patient with previous history of post-infectious rhombencephalitis who developed an acute disseminated encephalomyelitis (ADEM) two weeks after being vaccinated for COVID-19.

Automated summary

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection can lead to various nervous system complications, and a mass vaccination program is important for reducing long-term sequelae. However, it is crucial to report potential adverse events as more patients receive COVID-19 vaccines. Here, we present a case of acute disseminated encephalomyelitis (ADEM) in a patient with a history of post-infectious rhombencephalitis who developed the condition two weeks after receiving the COVID-19 vaccine.